常染色体显性多囊肾病治疗的新方向需求
常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾脏病,多数患者最终进展至肾衰竭。过去十年,随着托伐普坦等疾病修饰药物的批准,ADPKD管理已从支持治疗演变。本文综述了ADPKD治疗的现状与未来方向,包括已获批药物、在研的重新定位药物与创新疗法、饮食干预及基因治疗前景。
要点
- 目前唯一获批延缓ADPKD进展的药物是托伐普坦,意大利另批准奥曲肽长效释放剂用于CKD 4期患者。
- 多种药物正在临床研究中,包括SGLT2抑制剂、二甲双胍、GLP-1受体激动剂等重新定位药物。
- 创新疗法如抗PAPP-A单抗、microRNA-17抑制剂、多囊蛋白-1纠正剂VX-407及基因治疗处于实验或早期临床阶段。
核心结论
- ADPKD治疗已进入疾病修饰时代,但现有获批药物有限,亟需开发新治疗方向以延缓疾病进展。
研究设计与样本
- 综述,概述ADPKD治疗的当前状况与未来展望。
主要发现
- 目前唯一获批延缓ADPKD进展的药物是血管加压素V2受体拮抗剂托伐普坦;意大利还批准生长抑素类似物奥曲肽长效释放剂用于CKD 4期患者。
- 多种治疗策略正在临床研究中,包括重新定位的药物(钠-葡萄糖协同转运蛋白-2抑制剂、二甲双胍、胰高血糖素样肽-1受体激动剂)和创新疗法(抗妊娠相关血浆蛋白-A单克隆抗体、microRNA-17抑制剂、多囊蛋白-1纠正剂VX-407)。
- 饮食干预如热量限制和生酮饮食正在临床试验中测试,可能作为药物治疗的补充。
- 基因治疗在ADPKD领域进展迅速,目前仅在实验层面探索,未来可能转化为临床实践以纠正遗传缺陷。
临床怎么用
- 临床医生应了解托伐普坦是当前唯一获批延缓ADPKD进展的药物,并关注奥曲肽在意大利特定人群中的批准情况。
- 可向患者介绍正在进行的临床试验,包括重新定位药物、创新疗法及饮食干预,作为潜在治疗选择。
局限性
- 本文为综述,未报告原始研究数据;基因治疗等创新疗法尚处于实验阶段,临床证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and is characterized by the progressive growth of multiple kidney cysts, leading to kidney failure in most patients. The management of ADPKD, which up to a decade ago was limited to supportive measures to preserve kidney function and prevent complications, has evolved with the regulatory approval of disease-modifying agents. This review provided an overview of the current status and future perspectives of treatment for ADPKD. At present, the only drugs approved to slow disease progression are the vasopressin V2-receptor antagonist tolvaptan and, in Italy, the somatostatin analog octreotide long-acting release for the subset of patients with stage 4 CKD. However, various therapeutic strategies are under clinical investigation. These include not only repurposed pharmacological agents, namely sodium-glucose cotransporter-2 inhibitors, metformin, and glucagon-like peptide-1 receptor agonists, but also innovative therapies which is the case for a monoclonal antibody against pregnancy-associated plasma protein-A, microRNA-17 inhibitors, and the polycystin-1 correcting agent VX-407. Dietary interventions, such as caloric restriction and ketogenic diets, are being tested in clinical trials as well and could complement pharmacotherapy to slow disease progression. Moreover, the rapid advancements in the field of gene therapy for ADPKD suggest that this approach, though as yet only explored at experimental level, could be translated into clinical practice in future to correct the underlying genetic defect, and potentially reverse disease pathogenesis, thereby improving patient outcomes.
引用
- Cortinovis M, Perico N, Remuzzi G, et al. The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care. Clin J Am Soc Nephrol. 2025. PMID: 41348481. doi:10.2215/CJN.0000000975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。